PCA3 and prostate carcinoma: Some lncRNAs are already being used as biomarkers in the clinic such as the lncRNA Prostate cancer antigen 3 (PCA3) approved by the FDA as a prostate cancer biomarker, with a sensitivity of 58–82% and a 56–76% specificity [141].